Clinical Trial Update: Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets [Phase 1]

View source ↗

Summary

This Phase 1 bioequivalence study compares Bosentan 32 mg dispersible tablets to Tracleer 32 mg tablets in patients with Pulmonary Arterial Hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Bosentan (Bosentan)
• TRACLEER (bosentan)

Snippet

Sponsor: Humanis Saglık Anonim Sirketi | Conditions: Pulmonary Arterial Hypertension | Phase 1 | Status: COMPLETED